苯磺酸左旋氨氯地平治疗难治性高血压的研究

Study of Levoamlodipine besylate on intractable hypertension

目的观察苯磺酸左旋氨氯地平对难治性高血压的临床效验。方法依据中国高血压病防治指南选76例符合难治性高血压诊断标准的患者,随机分为苯磺酸左旋氨氯地平单药治疗组与联合治疗组(各组38例),观察2组治疗前后血压变化、血压达标及不良反应情况。结果治疗后血压达标联合组33例,达标率87%,单药组21例,达标率55%,联合组优于单药组(P<0.01)。联合组治疗前血压SBP(162.30±16.78)mmHg(1 mmHg=0.133 kPa)、DBP(104±6.82)mmHg,1周SBP(135.16±5.44)mmHg、DBP(93.17±3.18)mmHg,4周SBP(132.21±6.12)mmHg、DBP(85.33±4.25)mmHg,单药组治疗前血压SBP(164.25±14.36)mmHg、DBP(102.36±8.76)mmHg,1周SBP(148.42±10.78)mmHg,DBP(96.23±5.34)mmHg,4周SBP(144.59±8.84)mmHg、DBP(90.50±6.56)mmHg,2组治疗前后血压比较均有明显改善(P<0.05),治疗后1周、4周2组血压比较联合组优于单药组(P<0.05)。2组不良反应轻,耐受性好。结论苯磺酸左旋氨氯地平是一个通过拆分技术获得的新药,具有较好的依从性和降压效果,尤其是在治疗难治性高血压方面疗效确切。

Objective It is to observe the clinical effect of Levoamlodipine besylate on intractable hypertension. Methods According to control hypertension in China guide and hypertension diagnosis standards, 76 patients with intractable hypertension were chosen and randomly divided into levamlodipine besylate simple therapy group and combine therapy group （38 cases in each group）. The change of blood pressure, the blood pressure target hitting and untoward reaction in the two groups before and after treatment were observed. Results After treatment, the blood pressure target hitting in combine group was 33 cases and the target hitting ratio was 87 %, and that in simple group was 21 cases and the target hitting ratio was 55 %. The combine group was superior to the simple group （P 〈 0.01 ）. In combine group, before treatment SBP was （162.30 ± 16.78） mmHg （ 1 mmHg = 0. 133 kPa） and DBP was （ 104± 6.82） mmHg, after treatment for one week SBP was （135.16 ±5.44） mmHg and DBP was （93.17 ± 3.18） mmHg, and after treatment for four week SBP was （132.21 ± 6.12） mmHg and DBP was （85.33± 4.25） mmHg. In simple group, before treatment SBP was （164.25 ±14.36） mmHg and DBP was （102.36 ± 8.76） mmHg, after treatment for one week SBP was （148.42 ± 10.78） mmHg and DBP was （96.23± 5.34） mmHg, and after treatment for four week SBP was （144.59± 8.84） mmHg and DBP was （90.50±6.56） mmHg. There was obvious improvement on the blood pressure in the two groups before and after treatment （P 〈 0.05 ）. The blood pressure in combine group after treatment for one week and four week were superior to those in simple group （P 〈 0.05）. The two groups had light untoward reaction and good tolerance. Conclusion Levoamlodipine besylate is new drug through spilt technology which has good compliance and effective at lowering blood pressure, especially in treating intractable hypertension.